LILydia Inglezou

Lydia Inglezou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lydia Inglezou has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Sarcoidosis or Sarcoid-like Reaction? Diffuse Large B-Cell Lymphoma Diagnosed Months After Mediastinal Granulomas: A Case Report and Review of Published Cases

    by Styliani Voutidou, Christoforos Roumpakis, Lydia Inglezou, Paschalis Steiropoulos, Fotios Drakopanagiotakis

    Background and Clinical Significance: Sarcoidosis and lymphoma may precede, follow or accompany each other, and lymphoma can also induce a sarcoid-like granulomatous reaction. Case Presentation: We describe a 62-year-old woman with exertional dyspnea, abdominal pain and fluctuating cervical lymphadenopathy. Computed tomography showed mediastinal, hilar and abdominal lymphadenopathy with hepatosplenomegaly; a subcarinal lymph node obtained by mediastinoscopy showed non-necrotizing granulomas, and sarcoidosis was diagnosed and managed with observation. Four months later, worsening dyspnea and progressive lymphadenopathy led to FDG-PET/CT, which showed markedly hypermetabolic cervical nodes (SUVmax 20.5) but only moderate mediastinal uptake (SUVmax 4.8). Excisional cervical lymph node biopsy established diffuse large B-cell lymphoma (DLBCL), non-germinal-center B-cell phenotype, and Ann Arbor stage IIIS-A. After six cycles of R-CHOP, she achieved a complete metabolic response and remains in remission three years after treatment. Because both diagnoses were established within one year and lymphoma had initially been excluded on a single mediastinal node, a lymphoma already present at first presentation with an accompanying sarcoid-like reaction cannot be ruled out. Conclusions: In patients labeled as having sarcoidosis, peripheral or abdominal lymphadenopathy, splenomegaly and discordant FDG uptake should prompt excisional biopsy of the most accessible FDG-avid node, ideally before corticosteroids are started. Thirty-nine published cases of sarcoidosis associated with DLBCL are summarized.

  • Open Access

    The Role of Gut Microbiota in Acute Myeloid Leukemia

    by Lydia Maria Inglezou, Theocharis Konstantinidis, Aikaterini Skeva, Bouse Malkots, Emmanouil Panagiotopoulos, Vasiliki Sakka, Emmanouil Spanoudakis, Maria Panopoulou, Ioannis Kotsianidis, Konstantinos Liapis

    Gut microbiota plays a crucial role in regulating immune system function and shaping immunological responses to pathogens capable of causing infections. Alterations in the composition of the intestinal microbiome are associated with immune system dysfunction and increased susceptibility to infections. Patients with acute myeloid leukemia (AML) are highly susceptible to infections due to immune system deregulation caused by the disease itself, as well as chemotherapy-induced bone marrow aplasia. In these patients, gut microbiota dysbiosis and reduced microbial diversity (i.e., imbalances in the composition and function of intestinal microbes) result from multiple factors, including the underlying disease, neutropenia, dietary factors, use of antibiotics, chemotherapy regimens and prolonged hospitalization. Chemotherapy, for instance, induces damage to the intestinal mucosa and disrupts the epithelial barrier, resulting in deregulation of the intestinal microbiome. Previous studies have reported alterations in the human intestinal microbiome in patients with AML undergoing chemotherapy. Of particular interest is the capacity of some commensal bacteria to modulate the tumor microenvironment and response to chemotherapy. Moreover, increased mortality and reduced overall survival have been reported in patients who have undergone allogeneic stem cell transplantation and exhibit decreased gut microbiome diversity at the time of transplantation. These findings indicate that the composition of gut microbiota may play an important role in the prognosis of AML, especially in relation to therapeutic response. This narrative review summarizes new research into the role of the intestinal microbiome and the underlying alterations observed in patients with AML, resulting from the disease and therapeutic interventions and outlines strategies to improve its function and outcomes.


  • Open Access

    Clonal Hematopoiesis of Indeterminate Potential (CHIP): A Model of Mutation-Driven Thromboinflammation

    by Bouse Malkots, Iliana Stamatiou, Emmanuil Panagiotopoulos, Lydia Inglezou, Vasiliki Sakka, Georgios Vrachiolias, Christina Misidou, Emmanuil Spanoudakis, Ioannis Kotsianidis, Konstantinos Liapis

    Clonal hematopoiesis refers to the clonal expansion of hematopoietic stem and progenitor cells, driven by somatic mutations. Major mutated genes in clonal hematopoiesis include genes involved in epigenetic regulation including DNA methylation and/or chromatin modification (e.g., DNMT3A, TET2, and ASXL1), tumor suppressors (e.g., TP53), signal transduction (e.g., JAK2), and RNA splicing (e.g., SF3B1 and SRSF2). Clonal hematopoiesis includes clonal hematopoiesis of indeterminate potential (CHIP), clonal cytopenia of unknown significance (CCUS), and myelodysplastic syndromes/neoplasms (MDS). CHIP occurs when the frequency of the variant allele equals or exceeds 2% (4% for X-linked genes in males) in the absence of cytopenias. CHIP is common among older persons and is associated with an increased risk of hematologic cancer. CHIP is also associated with an increased risk of atherosclerotic disease including acute myocardial infarction, stroke, cardiac failure, and abdominal aneurysm. Increasing evidence suggests that CHIP is associated with venous thromboembolic disease. Somatic mutations lead to proliferation of hematopoietic progenitor cells and their progeny, resulting in excessive activation of granulocytes and monocytes. It could be postulated that chronic inflammation caused by clonal expansion of myeloid cells carrying mutations in DNMT3A, TET2, and ASXL1 (“DTA”) genes may constitute an independent risk factor in clot formation and endothelial-cell damage. DTA mutations correlate with elevated proinflammatory cytokines such as IL-1β and IL-6 and enhanced activation of inflammasomes. Moreover, JAK2 mutations may have a direct role in the activation of platelets and coagulation. In vivo murine studies have demonstrated that activation of the JAK-STAT signaling pathway promotes neutrophil extracellular trap (NET) formation, contributing to a prothrombotic state. Insights from related clonal disorders such as paroxysmal nocturnal hemoglobinuria and the VEXAS syndrome support the concept that mutation-driven innate immune activation can directly perturb hemostatic balance. This review aims to summarize the association between clonal expansion of hematopoietic cells and thrombotic disease, and highlight how somatic mutations in hematopoietic cells may contribute to vascular disease and thrombogenesis.


  • Open Access

    Maculopathy Linked to Light Chain Monoclonal Gammopathy: A Case Report

    by Christina Mitsi, Doukas Dardabounis, Lydia Inglezou, Konstantinos Liapis, Georgios Labiris, Tryfon Rotsos

    Monoclonal gammopathies can produce a spectrum of ocular manifestations, most commonly paraproteinemic keratopathy, but retinal involvement, though rare, may be vision‐threatening. We report a case of paraproteinemic maculopathy in a 49‐year‐old female with a history of hypertension and albuminuria, who presented with blurred vision and renal impairment. Examination revealed subretinal yellow infiltrates in the posterior pole with hyperautofluorescence on fundus autofluorescence and subretinal fluid with hyperreflective deposits above the retinal pigment epithelium on optical coherence tomography. Laboratory workup identified an excess of free kappa light chains in serum. A diagnosis of light chain deposition disease (LCDD) was made on the basis of a renal biopsy, and systemic therapy was initiated. At 5 months posttreatment, best‐corrected visual acuity improved to 20/20 OU, with resolution of subretinal fluid, although sub‐RPE deposits persisted. This case illustrates that monoclonal free light chains can induce maculopathy through RPE and choroidal depositions, mimicking other macular diseases. Early recognition and systemic treatment targeting the underlying plasma cell disorder are essential for visual recovery. Ophthalmologists should maintain a high index of suspicion for paraproteinemic maculopathy in patients with atypical serous macular detachments, particularly when the findings are bilateral or associated with subtle systemic signs, emphasizing the need for a multidisciplinary approach.

  • Severe Hypocalcemia Due to Skeletal Remineralization After Venetoclax, Bortezomib, and Dexamethasone for Relapsed Multiple Myeloma

    by Lydia Inglezou, Giolanta Tsekou, Ioannis Kotsianidis, Emmanouil Spanoudakis, Konstantinos Liapis